Postpartum circulating microRNA enhances prediction of future type 2 diabetes in women with previous gestational diabetes.
Circulating biomarkers
Gestational diabetes
Machine learning
OGTT
Observational cohort
Postpartum
Real-time PCR
Receiver operating characteristic (ROC) curve
Risk prediction
Type 2 diabetes
microRNAs
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
11
10
2020
accepted:
14
01
2021
pubmed:
24
3
2021
medline:
11
3
2022
entrez:
23
3
2021
Statut:
ppublish
Résumé
Type 2 diabetes mellitus is a major cause of morbidity and death worldwide. Women with gestational diabetes mellitus (GDM) have greater than a sevenfold higher risk of developing type 2 diabetes in later life. Accurate methods for postpartum type 2 diabetes risk stratification are lacking. Circulating microRNAs (miRNAs) are well recognised as biomarkers/mediators of metabolic disease. We aimed to determine whether postpartum circulating miRNAs can predict the development of type 2 diabetes in women with previous GDM. In an observational study, plasma samples were collected at 12 weeks postpartum from 103 women following GDM pregnancy. Utilising a discovery approach, we measured 754 miRNAs in plasma from type 2 diabetes non-progressors (n = 11) and type 2 diabetes progressors (n = 10) using TaqMan-based real-time PCR on an OpenArray platform. Machine learning algorithms involving penalised logistic regression followed by bootstrapping were implemented. Fifteen miRNAs were selected based on their importance in discriminating type 2 diabetes progressors from non-progressors in our discovery cohort. The levels of miRNA miR-369-3p remained significantly different (p < 0.05) between progressors and non-progressors in the validation sample set (n = 82; 71 non-progressors, 11 progressors) after adjusting for age and correcting for multiple comparisons. In a clinical model of prediction of type 2 diabetes that included six traditional risk factors (age, BMI, pregnancy fasting glucose, postpartum fasting glucose, cholesterol and triacylglycerols), the addition of the circulating miR-369-3p measured at 12 weeks postpartum improved the prediction of future type 2 diabetes from traditional AUC 0.83 (95% CI 0.68, 0.97) to an AUC 0.92 (95% CI 0.84, 1.00). This is the first demonstration of miRNA-based type 2 diabetes prediction in women with previous GDM. Improved prediction will facilitate early lifestyle/drug intervention for type 2 diabetes prevention.
Identifiants
pubmed: 33755745
doi: 10.1007/s00125-021-05429-z
pii: 10.1007/s00125-021-05429-z
doi:
Substances chimiques
Biomarkers
0
Circulating MicroRNA
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1516-1526Références
Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 157:107843. https://doi.org/10.1016/j.diabres.2019.107843
doi: 10.1016/j.diabres.2019.107843
pubmed: 31518657
Nguyen-Ngo C, Jayabalan N, Salomon C, Lappas M (2019) Molecular pathways disrupted by gestational diabetes mellitus. J Mol Endocrinol 63(3):R51–R72. https://doi.org/10.1530/JME-18-0274
doi: 10.1530/JME-18-0274
pubmed: 31416051
Catalano PM (2014) Trying to understand gestational diabetes. Diabet Med 31(3):273–281. https://doi.org/10.1111/dme.12381
doi: 10.1111/dme.12381
pubmed: 24341419
pmcid: 4178541
McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P (2019) Gestational diabetes mellitus. Nat Rev Dis Primers 5(1):47. https://doi.org/10.1038/s41572-019-0098-8
doi: 10.1038/s41572-019-0098-8
pubmed: 31296866
Johns EC, Denison FC, Norman JE, Reynolds RM (2018) Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab 29(11):743–754. https://doi.org/10.1016/j.tem.2018.09.004
doi: 10.1016/j.tem.2018.09.004
pubmed: 30297319
Feig DS, Shah BR, Lipscombe LL et al (2013) Preeclampsia as a risk factor for diabetes: a population-based cohort study. PLoS Med 10(4):UNSP e1001425. https://doi.org/10.1371/journal.pmed.1001425
doi: 10.1371/journal.pmed.1001425
Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL (2020) Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ 369:m1361. https://doi.org/10.1136/bmj.m1361
doi: 10.1136/bmj.m1361
pubmed: 32404325
pmcid: 7218708
Rayanagoudar G, Hashi AA, Zamora J, Khan KS, Hitman GA, Thangaratinam S (2016) Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women. Diabetologia 59(7):1403–1411. https://doi.org/10.1007/s00125-016-3927-2
doi: 10.1007/s00125-016-3927-2
pubmed: 27073002
pmcid: 4901120
Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403. https://doi.org/10.1056/NEJMoa012512
doi: 10.1056/NEJMoa012512
pubmed: 11832527
Ratner RE (2007) Prevention of type 2 diabetes in women with previous gestational diabetes. Diabetes Care 30(Suppl 2):S242–S245. https://doi.org/10.2337/dc07-s223
doi: 10.2337/dc07-s223
pubmed: 17596479
Metzger BE, Buchanan TA, Coustan DR et al (2007) Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 30(Suppl 2):S251–S260. https://doi.org/10.2337/dc07-s225
doi: 10.2337/dc07-s225
pubmed: 17596481
American Diabetes Association (2014) Standards of medical care in diabetes--2014. Diabetes Care 37(Suppl 1):S14–S80. https://doi.org/10.2337/dc14-S014
doi: 10.2337/dc14-S014
Shah BR, Lipscombe LL, Feig DS, Lowe JM (2011) Missed opportunities for type 2 diabetes testing following gestational diabetes: a population-based cohort study. BJOG 118(12):1484–1490. https://doi.org/10.1111/j.1471-0528.2011.03083.x
doi: 10.1111/j.1471-0528.2011.03083.x
pubmed: 21864326
Fahami R, Dhalwani N, Khunti K, Davies M, Seidu S (2019) Postpartum monitoring of women with a history of gestational diabetes - a cross-sectional study of an inner-city population. Prim Care Diabetes 13(4):376–379. https://doi.org/10.1016/j.pcd.2018.11.010
doi: 10.1016/j.pcd.2018.11.010
pubmed: 30583931
Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L (2009) Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 32(2):281–286. https://doi.org/10.2337/dc08-1264
doi: 10.2337/dc08-1264
pubmed: 19017778
pmcid: 2628694
Lappas M, Jinks D, Shub A, Willcox JC, Georgiou HM, Permezel M (2016) Postpartum IGF-I and IGFBP-2 levels are prospectively associated with the development of type 2 diabetes in women with previous gestational diabetes mellitus. Diabetes Metab 42(6):442–447. https://doi.org/10.1016/j.diabet.2016.06.004
doi: 10.1016/j.diabet.2016.06.004
pubmed: 27387739
Lappas M, Mundra PA, Wong G et al (2015) The prediction of type 2 diabetes in women with previous gestational diabetes mellitus using lipidomics. Diabetologia 58(7):1436–1442. https://doi.org/10.1007/s00125-015-3587-7
doi: 10.1007/s00125-015-3587-7
pubmed: 25893729
Lappas M, Jinks D, Ugoni A, Louizos CC, Permezel M, Georgiou HM (2015) Post-partum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus. J Diabetes 7(4):506–511. https://doi.org/10.1111/1753-0407.12209
doi: 10.1111/1753-0407.12209
pubmed: 25168970
Pan R, Zhang H, Yu S et al (2019) Betatrophin for diagnosis and prognosis of mothers with gestational diabetes mellitus. J Int Med Res 47(2):710–717. https://doi.org/10.1177/0300060518808683
doi: 10.1177/0300060518808683
pubmed: 30392425
Pinnaduwage L, Ye C, Hanley AJ et al (2018) Changes over time in hepatic markers predict changes in insulin sensitivity, beta-cell function, and glycemia. J Clin Endocrinol Metab 103(7):2651–2659. https://doi.org/10.1210/jc.2018-00306
doi: 10.1210/jc.2018-00306
pubmed: 29897453
Dudzik D, Zorawski M, Skotnicki M et al (2017) GC-MS based gestational diabetes mellitus longitudinal study: identification of 2-and 3-hydroxybutyrate as potential prognostic biomarkers. J Pharmaceut Biomed 144:90–98. https://doi.org/10.1016/j.jpba.2017.02.056
doi: 10.1016/j.jpba.2017.02.056
Katra P, Dereke J, Nilsson C, Hillman M (2016) Plasma levels of the Interleukin-1-receptor antagonist are lower in women with gestational diabetes mellitus and are particularly associated with postpartum development of type 2 diabetes. PLoS One 11(5):e0155701. https://doi.org/10.1371/journal.pone.0155701
doi: 10.1371/journal.pone.0155701
pubmed: 27223471
pmcid: 4880279
Michalczyk AA, Dunbar JA, Janus ED et al (2016) Epigenetic markers to predict conversion from gestational diabetes to type 2 diabetes. J Clin Endocrinol Metab 101(6):2396–2404. https://doi.org/10.1210/jc.2015-4206
doi: 10.1210/jc.2015-4206
pubmed: 27045797
Khan SR, Mohan H, Liu Y et al (2019) The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes. Diabetologia 62(4):687–703. https://doi.org/10.1007/s00125-018-4800-2
doi: 10.1007/s00125-018-4800-2
pubmed: 30645667
pmcid: 7237273
Lai M, Liu Y, Ronnett GV et al (2020) Amino acid and lipid metabolism in post-gestational diabetes and progression to type 2 diabetes: a metabolic profiling study. PLoS Med 17(5):e1003112. https://doi.org/10.1371/journal.pmed.1003112
doi: 10.1371/journal.pmed.1003112
pubmed: 32433647
pmcid: 7239388
Wong WKM, Sorensen AE, Joglekar MV, Hardikar AA, Dalgaard LT (2018) Non-coding RNA in pancreas and β-cell development. Noncoding RNA 4(4):41. https://doi.org/10.3390/ncrna4040041
doi: 10.3390/ncrna4040041
pmcid: 6315983
Bartel DP (2018) Metazoan microRNAs. Cell 173(1):20–51. https://doi.org/10.1016/j.cell.2018.03.006
doi: 10.1016/j.cell.2018.03.006
pubmed: 29570994
pmcid: 6091663
Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101(10):2087–2092. https://doi.org/10.1111/j.1349-7006.2010.01650.x
doi: 10.1111/j.1349-7006.2010.01650.x
pubmed: 20624164
Farr RJ, Joglekar MV, Taylor CJ, Hardikar AA (2013) Circulating non-coding RNAs as biomarkers of beta cell death in diabetes. Pediatr Endocrinol Rev 11(1):14–20
pubmed: 24079075
Lappas M, Georgiou HM, Willcox JC et al (2019) Postpartum circulating cell-free insulin DNA levels are higher in women with previous gestational diabetes mellitus who develop type 2 diabetes in later life. J Diabetes Res 2019:3264184. https://doi.org/10.1155/2019/3264184
doi: 10.1155/2019/3264184
pubmed: 31428654
pmcid: 6681610
Genuth S, Alberti KG, Bennett P et al (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26(11):3160–3167. https://doi.org/10.2337/diacare.26.11.3160
doi: 10.2337/diacare.26.11.3160
pubmed: 14578255
Kok MGM, de Ronde MWJ, Moerland PD, Ruijter JM, Creemers EE, Pinto-Sietsma SJ (2018) Small sample sizes in high-throughput miRNA screens: a common pitfall for the identification of miRNA biomarkers. Biomol Detect Quantif 15:1–5. https://doi.org/10.1016/j.bdq.2017.11.002
doi: 10.1016/j.bdq.2017.11.002
pubmed: 29276692
Farr RJ, Januszewski AS, Joglekar MV et al (2015) A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Sci Rep 5:10375. https://doi.org/10.1038/srep10375
doi: 10.1038/srep10375
pubmed: 26035063
pmcid: 4649912
Wong W, Farr R, Joglekar M, Januszewski A, Hardikar A (2015) Probe-based real-time PCR approaches for quantitative measurement of microRNAs. J Vis Exp 98:52586. https://doi.org/10.3791/52586
doi: 10.3791/52586
Hardikar AA, Farr RJ, Joglekar MV (2014) Circulating microRNAs: understanding the limits for quantitative measurement by real-time PCR. J Am Heart Assoc 3(1):e000792. https://doi.org/10.1161/JAHA.113.000792
doi: 10.1161/JAHA.113.000792
pubmed: 24572259
pmcid: 3959687
Goeman JJ (2010) L1 penalized estimation in the Cox proportional hazards model. Biom J 52(1):70–84. https://doi.org/10.1002/bimj.200900028
doi: 10.1002/bimj.200900028
pubmed: 19937997
Lu TP, Lee CY, Tsai MH et al (2012) miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS One 7(8):e42390. https://doi.org/10.1371/journal.pone.0042390
doi: 10.1371/journal.pone.0042390
pubmed: 22870325
pmcid: 3411648
Barraclough JY, Joglekar MV, Januszewski AS et al (2020) A MicroRNA signature in acute coronary syndrome patients and modulation by colchicine. J Cardiovasc Pharmacol Ther 25(5):444–455. https://doi.org/10.1177/1074248420922793
doi: 10.1177/1074248420922793
pubmed: 32356454
Shihana F, Joglekar MV, Raubenheimer J, Hardikar AA, Buckley NA, Seth D (2020) Circulating human microRNA biomarkers of oxalic acid-induced acute kidney injury. Arch Toxicol 94(5):1725–1737. https://doi.org/10.1007/s00204-020-02679-5
doi: 10.1007/s00204-020-02679-5
pubmed: 32086547
Catalano PM, Shankar K (2017) Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. BMJ 356:j1. https://doi.org/10.1136/bmj.j1
doi: 10.1136/bmj.j1
pubmed: 28179267
pmcid: 6888512
Kameswaran V, Bramswig NC, McKenna LB et al (2014) Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab 19(1):135–145. https://doi.org/10.1016/j.cmet.2013.11.016
doi: 10.1016/j.cmet.2013.11.016
pubmed: 24374217
Aichler M, Borgmann D, Krumsiek J et al (2017) N-acyl taurines and acylcarnitines cause an imbalance in insulin synthesis and secretion provoking beta cell dysfunction in type 2 diabetes. Cell Metab 25(6):1334–1347 e1334. https://doi.org/10.1016/j.cmet.2017.04.012
doi: 10.1016/j.cmet.2017.04.012
pubmed: 28591636
Merezak S, Hardikar AA, Yajnik CS, Remacle C, Reusens B (2001) Intrauterine low protein diet increases fetal beta-cell sensitivity to NO and IL-1 beta: the protective role of taurine. J Endocrinol 171(2):299–308. https://doi.org/10.1677/joe.0.1710299
doi: 10.1677/joe.0.1710299
pubmed: 11691650
Filardi T, Catanzaro G, Mardente S et al (2020) Non-coding RNA: role in gestational diabetes pathophysiology and complications. Int J Mol Sci 21:11. https://doi.org/10.3390/ijms21114020
doi: 10.3390/ijms21114020
Zhao C, Dong J, Jiang T et al (2011) Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One 6(8):e23925. https://doi.org/10.1371/journal.pone.0023925
doi: 10.1371/journal.pone.0023925
pubmed: 21887347
pmcid: 3161072
Wander PL, Boyko EJ, Hevner K et al (2017) Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes. Diabetes Res Clin Pract 132:1–9. https://doi.org/10.1016/j.diabres.2017.07.024
doi: 10.1016/j.diabres.2017.07.024
pubmed: 28783527
pmcid: 5623075
Tagoma A, Alnek K, Kirss A, Uibo R, Haller-Kikkatalo K (2018) MicroRNA profiling of second trimester maternal plasma shows upregulation of miR-195-5p in patients with gestational diabetes. Gene 672:137–142. https://doi.org/10.1016/j.gene.2018.06.004
doi: 10.1016/j.gene.2018.06.004
pubmed: 29879500
Yoffe L, Polsky A, Gilam A et al (2019) Early diagnosis of gestational diabetes mellitus using circulating microRNAs. Eur J Endocrinol 181(5):565–577. https://doi.org/10.1530/Eje-19-0206
doi: 10.1530/Eje-19-0206
pubmed: 31539877
Sebastiani G, Guarino E, Grieco GE et al (2017) Circulating microRNA (miRNA) expression profiling in plasma of patients with gestational diabetes mellitus reveals upregulation of miRNA miR-330-3p. Front Endocrinol (Lausanne) 8:345. https://doi.org/10.3389/fendo.2017.00345
doi: 10.3389/fendo.2017.00345
Pfeiffer S, Sanchez-Lechuga B, Donovan P et al (2020) Circulating miR-330-3p in late pregnancy is associated with pregnancy outcomes among lean women with GDM. Sci Rep 10(1):908. https://doi.org/10.1038/s41598-020-57838-6
doi: 10.1038/s41598-020-57838-6
pubmed: 31969632
pmcid: 6976655